米力农治疗难治性脑血管痉挛伴迟发性脑缺血
该回顾性队列研究纳入2010至2016年蒙特利尔神经病学研究所收治的322例动脉瘤性蛛网膜下腔出血患者,分析静脉米力农治疗难治性血管痉挛/迟发性脑缺血(DCI)的预测因素及动脉内米力农和/或机械血管成形术的补救治疗结局。19%的患者接受补救治疗,动脉内米力农使32%的难治性痉挛血管逆转,76%的患者神经状态在24小时内显著改善;中重度影像学血管痉挛独立预测补救治疗需求(OR 27,95%CI 8.01-112)。作者结论认为积极使用米力农是安全有效的。
要点
- 19%(21/110)的DCI患者出现难治性血管痉挛并接受补救治疗。
- 动脉内米力农逆转32%(29/91)的难治性痉挛血管,76%(16/21)患者24小时内神经状态显著改善。
- 中重度影像学血管痉挛独立预测补救治疗需求(OR 27,95%CI 8.01-112)。
核心结论
- 基于该回顾性队列,积极使用米力农是安全有效的,是治疗aSAH后血管痉挛/DCI的有前景疗法。
研究设计与样本
- 回顾性队列研究,纳入2010至2016年蒙特利尔神经病学研究所收治的所有aSAH患者,共322例,分为无DCI组(212例)、标准治疗组(89例)和补救治疗组(21例)。
主要发现
- 52%(168/322)的患者在治疗决策时为差级别aSAH(WFNS分级III-V级)。
- 在有DCI且影像评估血管痉挛严重程度的患者中,62%(68/109)在DCI表现时有中重度影像学血管痉挛。
- 19%(21/110)的患者出现难治性血管痉挛/DCI并接受补救治疗。
- 动脉内米力农逆转32%(29/91)的难治性痉挛血管,76%(16/21)的患者在开始治疗后24小时内神经状态显著改善。
- 中重度影像学血管痉挛独立预测补救治疗需求(OR 27,95%CI 8.01-112)。
关键数值与推荐
- 出院前神经影像发现新发脑梗死者占40%(112/277),其中仅21%(23/112)为血管痉挛相关。
- 65%(204/314)的患者在aSAH后中位4个月(四分位距2-8个月)评估时功能结局良好(mRS评分0-2),三组间功能结局无差异(p=0.512)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intravenous (IV) milrinone is a promising option for the treatment of cerebral vasospasm with delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage (aSAH). However, data remain limited on the efficacy of treating cases that are refractory to standard therapy with IV milrinone. The aim of this study was to determine predictors of refractory vasospasm/DCI despite treatment with IV milrinone, and to analyze the outcome of rescue therapy with intraarterial (IA) milrinone and/or mechanical angioplasty. METHODS: The authors conducted a retrospective cohort study of all patients with aSAH admitted between 2010 and 2016 to the Montreal Neurological Institute and Hospital. Patients were stratified into 3 groups: no DCI, standard therapy, and rescue therapy. The primary outcome was frequency of DCI-related cerebral infarction identified on neuroimaging before hospital discharge. Secondary outcomes included functional outcome reported as modified Rankin Scale (mRS) score, and segment reversal of refractory vasospasm. RESULTS: The cohort included 322 patients: 212 in the no DCI group, 89 in the standard therapy group, and 21 in the rescue therapy group. Approximately half (52%, 168/322) were admitted with poor-grade aSAH at treatment decision (World Federation of Neurosurgical Societies grade III-V). Among patients with DCI and imaging assessing severity of vasospasm, 62% (68/109) had moderate/severe radiological vasospasm on DCI presentation. Nineteen percent (21/110) of patients had refractory vasospasm/DCI and were treated with rescue therapy. Targeted rescue therapy with IA milrinone reversed 32% (29/91) of the refractory vasospastic vessels, and 76% (16/21) of those patients experienced significant improvement in their neurological status within 24 hours of initiating therapy. Moderate/severe radiological vasospasm independently predicted the need for rescue therapy (OR 27, 95% CI 8.01-112). Of patients with neuroimaging before discharge, 40% (112/277) had developed new cerebral infarcts, and only 21% (23/112) of these were vasospasm-related. Overall, 65% (204/314) of patients had a favorable functional outcome (mRS score 0-2) assessed at a median of 4 months (interquartile range 2-8 months) after aSAH, and there was no difference in functional outcome between the 3 groups (p = 0.512). CONCLUSIONS: The aggressive use of milrinone was safe and effective based on this retrospective study cohort and is a promising therapy for the treatment of vasospasm/DCI after aSAH.
引用
- Abulhasan YB, Ortiz Jimenez J, Teitelbaum J, et al. Milrinone for refractory cerebral vasospasm with delayed cerebral ischemia. J Neurosurg. 2020. PMID: 32217799. doi:10.3171/2020.1.JNS193107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。